In a social media live event organised by the World Health Organisation from Geneva, the scientist said that more waves of the infection would be required to get to a stage of natural immunity

Already, over 3,500 volunteers have registered themselves for the trial at AIIMS since last Saturday, of whom the screening of at least 22 people is underway, said Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS

Favipiravir, which is used to treat mild to moderate COVID-19 patients, will be commercially launched under the brand name Ciplenza in the first week of August, priced at Rs 68 per tablet

Coronavirus (Covid-19) Vaccine News Latest Updates:  The study showed that curcumin can prevent Transmissible gastroenteritis virus (TGEV)- an alpha-group coronavirus that infects pigs, from infecting cells. The higher doses of curcumin were also found to kill virus particles

Coronavirus (Covid-19) Vaccine News Latest Updates: Head of WHO's emergencies programme Mike Ryan has said that while there are multiple contenders and many companies have made significant progress, the likely time for a coronavirus vaccine in the market is not before 2021

The Serum Institute of India will begin phase-III human clinical trials of the COVID-19 vaccine in the country in August with 4,000-5,000 volunteers, said its CEO Adar Poonawalla

At the interbank forex market, the domestic unit opened at 74.61 per dollar and later gained further ground to touch 74.59, registering a gain of 15 paise over its previous close of 74.74 per dollar on Tuesday

Serum Institute of India CEO Adar Poonawalla expressed certitude that the governments across low-and-middle-income nations will procure and distribute the COVID-19 vaccine without charge

Covaxin, an experimental novel coronavirus vaccine developed by Hyderabad-based Bharat Biotech, has begun human trials at New Delhi's All India Institute of Medical Sciences this week. AIIMS-New Delhi is one the 12 sites chosen by the Indian Council of Medical Research, which is a collaborator on the Covaxin novel coronavirus vaccine project, for conducting human trials. How much time will this vaccine take, how many trials will take place and where. Watch the video to know more.Govt warns 59 Chinese apps of serious action if found operating despite ban

Coronavirus (COVID-19) Vaccine News Latest Updates: Dr Cyrus Poonawalla, Chairman of the Poonawalla Group, says a just a few million doses of the potential COVID-19 vaccine will not be enough and the company intends to manufacture around 1 billion doses after getting all the necessary approvals

Meanwhile, CRISIL, DCM Shriram, SBI Life and SML Isuzu are among the top companies that will report their April-June quarterly earnings. Axis Bank, Bajaj Finance, Bajaj Finserv, HDFC Life Insurance, ICICI Prudential reported their quarterly earnings during today's session

At the interbank forex market, rupee opened at 74.79 per dollar and later gained further ground to touch 74.73 per dollar, up 18 paise over its previous close of 74.91 on Monday.

Vaccine major Serum Institute of India's CEO Adar Poonawalla said on Monday the company will apply for COVID-19 vaccine trials within a week and will soon begin manufacturing the vaccine, developed by Oxford University, in large volumes

Oxford coronavirus vaccine shows promise, can train immune systemThe human trials of coronavirus vaccine candidate developed by the University of Oxford and backed by AstraZeneca Plc has shown positive results. The first phase of human trials of vaccine, officially known as AZD1222, have appeared to be safe and prompted a protective immune response in hundreds of people who got the shot, as per a report published in British medical journal Lancet.Sony to own 74% after merger with Viacom 18;...

Stock Market Highlights on July 21: ICICI Bank, followed by Maruti, Kotak Bank, Axis Bank, Power Grid and HDFC Bank were among the top gainers today, while Bajaj Finserv and ITC were the top laggards.

COVAXIN is the first indigenous coronavirus vaccine, being developed by Hyderabad-based Bharat Biotech and Indian Council of Medical Research (ICMR). AIIMS, Delhi is one of the 12 facilities shortlisted by ICMR for conducting clinical trials of Covaxin

Coronavirus vacciine update: Trials on 1,077 people showed that the vaccine, officially known as AZD1222, led to generation of antibodies and white blood cells that can fight coronavirus

Hyderabad-based Bharat Bharat Biotech India (BBIL) in collaboration with ICMR's National Institute of Virology (NIV) has developed India's first indigenous COVID-19 vaccine candidate Covaxin

Covaxin is being jointly developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology and is India's first indigenously developed COVID-19 vaccine candidate

The study findings could help high-risk countries with population screening, case identification, contact tracing, confirming vaccine efficacy during clinical trials, and vaccine distribution, the statement said